Law360, New York (September 10, 2009, 6:24 PM EDT) -- A federal appeals court has struck down a ruling in an infringement suit brought by Sanofi-Aventis US LLC against a slew of generics makers, saying the lower court erred when it said the generics manufacturers had not infringed on Sanofi’s patent for popular colon cancer drug Eloxatin.
The U.S. Court of Appeals for the Federal Circuit on Wednesday vacated and remanded a summary judgment ruling back to the U.S. District Court for the District of New Jersey.
Sanofi filed the suit in June 2007, accusing generic-drug...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.